Cerenis licenses IP on AVS

Cerenis Therapeutics SA, a privately-held French pharmaceutical company developing treatments for cardiovascular and metabolic diseases,  has in-licensed intellectual property supporting an investigational new  treatment of aortic valve stenosis based on high-density lipoprotein  therapy. This technology is based on the findings of a study led by  Jean-Claude Tardif, at the Montreal Heart Institute Research Centre in  Canada. AVS is characterized by a narrowing of the aortic valve and can  cause a potentially dangerous imbalance in blood pressure and results in  over 50,000 aortic valve replacement surgeries each year in the USA.